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Abstract
Background: Chronic Hepatitis B Virus (HBV) infection is characterised by the persistence of hepatitis B surface
antigen (HBsAg). Expanding HBV diagnosis and treatment programmes into low resource settings will require high
quality but inexpensive rapid diagnostic tests (RDTs) in addition to laboratory-based enzyme immunoassays (EIAs)
to detect HBsAg. The purpose of this review is to assess the clinical accuracy of available diagnostic tests to detect
HBsAg to inform recommendations on testing strategies in 2017 WHO hepatitis testing guidelines.
Methods: The systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guidelines using 9 databases. Two reviewers independently extracted data according
to a pre-specified plan and evaluated study quality. Meta-analysis was performed. HBsAg diagnostic accuracy of
rapid diagnostic tests (RDTs) was compared to enzyme immunoassay (EIA) and nucleic-acid test (NAT) reference
standards. Subanalyses were performed to determine accuracy among brands, HIV-status and specimen type.
Results: Of the 40 studies that met the inclusion criteria, 33 compared RDTs and/or EIAs against EIAs and 7
against NATs as reference standards. Thirty studies assessed diagnostic accuracy of 33 brands of RDTs in 23,716
individuals from 23 countries using EIA as the reference standard. The pooled sensitivity and specificity were 90.0%
(95% CI: 89.1, 90.8) and 99.5% (95% CI: 99.4, 99.5) respectively, but accuracy varied widely among brands. Accuracy did
not differ significantly whether serum, plasma, venous or capillary whole blood was used. Pooled sensitivity of RDTs in
5 studies of HIV-positive persons was lower at 72.3% (95% CI: 67.9, 76.4) compared to that in HIV-negative persons, but
specificity remained high. Five studies evaluated 8 EIAs against a chemiluminescence immunoassay reference standard
with a pooled sensitivity and specificity of 88.9% (95% CI: 87.0, 90.6) and 98.4% (95% CI: 97.8, 98.8), respectively.
Accuracy of both RDTs and EIAs using a NAT reference were generally lower, especially amongst HIV-positive cohorts.
Conclusions: HBsAg RDTs have good sensitivity and excellent specificity compared to laboratory immunoassays as a
reference standard. Sensitivity of HBsAg RDTs may be lower in HIV infected individuals.
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Background
An estimated 257 million individuals worldwide are
chronically infected with hepatitis B virus (HBV), of
whom 2.7 million are co-infected with HIV [1]. Globally,
between 20 and 30% of patients with chronic HBV infec-
tion will develop cirrhosis or hepatocellular carcinoma
[2], accounting for the majority of the attributable 686,
000 deaths [3] and 21 million disability-adjusted life-
years annually [4]. Most individuals with chronic HBV
infection however are not aware of their serostatus. De-
layed diagnosis means that many may progress to long
term complications and present only with advanced dis-
ease [5]. Expanded access to testing for HBV is critically
important in order to increase numbers of infected indi-
viduals aware of their status for linkage to care, as well
as identifying candidates for HBV vaccination and facili-
tating prevention and control efforts.
In March 2015 the World Health Organization
(WHO) published the first global guidelines for the pre-
vention, care, and treatment of individuals with chronic
HBV infection [5]. These guidelines focused on assess-
ment for treatment eligibility, initiation of first and
second-line therapies, and monitoring. These initial
guidelines did not include testing recommendations, and
in particular which tests to use. Given the large burden
of HBV in low and middle income settings where there
are limited or no existing HBV testing guidelines, the
development of HBV testing guidelines is a priority.
Advances in HBV detection technology have created
new opportunities for testing, referral, and treatment.
Chronic HBV infection is defined as persistence of hepa-
titis B surface antigen (HBSAg) for at least six months,
and the testing strategy involves an initial serological test
to detect HBsAg followed by nucleic-acid amplification
test (NAT) for detection of HBV DNA viral load to help
guide treatment decisions [5]. HBsAg can be detected
using rapid diagnostic tests (RDTs) in lateral flow,
flow through or simple agglutination assays formats.
Laboratory-based immunoassays to detect HBsAg in-
clude traditional radioimmunoassays (RIA) and enzyme
immunoassays (EIA), as well as newer technologies such
as electrochemiluminescence immunoassays (ECLIA),
microparticle enzyme immunoassays (MEIA) and
chemiluminescent microparticle immunoassays (CMIA),
which use signal amplification to give quantitative
measurements.
Previous systematic reviews on HBV infection have fo-
cused on effectiveness of immune responses to HBV vac-
cination [6], surveillance of cirrhosis [7], and evaluation
of treatment effectiveness [8]. Prior reviews on hepatitis
B testing [9–11] only focused on the performance of
tests that can be used at the point of care. They also in-
cluded evaluations with unclear reference standards and
studies that used serum panels to evaluate test
performance, which are inappropriate for assessing clin-
ical or operational diagnostic accuracy in the field. This
review aimed to assess the diagnostic accuracy of assays
used to detect HBsAg in order to inform WHO and
other guidelines on hepatitis testing [12]. This was the
first study exclusively comparing the clinical perform-
ance of both RDTs and laboratory-based immunoassays,
in addition to addressing the question of accuracy in the
context of HIV status. The accuracy of HBsAg assays
against a NAT reference standard was also undertaken,
given the importance of reducing transmission during
the seroconversion period and in the diagnosis of occult
hepatitis B where HBsAg may not be detectable, which
is more common with HIV co-infection. The purpose of
this review was to provide quantitative evidence of the
accuracy of available diagnostics to detect HBsAg in
order to inform global guidelines.
Methods
Search strategy and identification of studies
We conducted a systematic review and meta-analysis on
the diagnostic accuracy of HBsAg tests. The review was
registered in PROSPERO (CRD42015020313) and re-
ported in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA)
check list. We utilised standardised methods for system-
atic reviews on diagnostics, including an a priori proto-
col (Additional file 1).
Literature search strategies were developed by a med-
ical librarian with expertise in systematic review search-
ing, using a search algorithm consisting of terms for:
hepatitis B, diagnostic tests, and diagnostic accuracy. We
searched MEDLINE, EMBASE, the Cochrane Central
Register of Controlled Trials, Science Citation Index
Expanded, SCOPUS, Literatura Latino-Americana e do
Caribe em Ciências da Saúde (LILACS), WHO Global
Index Medicus, WHO’s International Clinical Trials
Registry and the Web of Science. We also contacted re-
searchers, experts and authors of major trials, with no
relevant manuscripts in preparation identified. Add-
itional pertinent citations were identified through bibli-
ographies of retrieved studies.
Abstracts were screened by reviewers AA and HK ac-
cording to standard inclusion and exclusion criteria. All
studies identified for full manuscript review were
assessed independently by two reviewers (AA and OV)
against inclusion criteria. Papers were accepted or
rejected, with reasons for exclusion specified. Discrepan-
cies were resolved by discussion between review authors
and, when required, a third independent reviewer (RP).
Selection criteria
Inclusion criteria were: case-control, cross-sectional, co-
hort studies or randomized trials published between
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1996 and May 2015; primary purpose of evaluating
HBsAg test accuracy; commercially available laboratory
immunoassays or NAT as reference standard; any clin-
ical specimen type. We excluded: articles in languages
other than English; conference abstracts, comments or
review papers; studies only reporting sensitivity or speci-
ficity without reference standards; studies using com-
mercially prepared reference panels.
We included studies reporting original data from pa-
tient specimens in all age groups, settings, countries and
specimen types. We performed a sub-analysis comparing
test accuracy before 2005 with more recent studies pub-
lished between 2005 and 2015 as the accuracy of refer-
ence standard immunoassays has improved over time.
This time period was chosen as it was 10 years prior to
the literature search, matched with a similar meta-
analysis on hepatitis C tests (Ref Paper 11), and was
around the time of the last WHO review of HbsAg assay
operational characteristics [13]. Studies comparing the
accuracy of laboratory based immunoassays were only
included if they used CMIAs as the reference standard;
most excluded studies using other platforms included
reference panels, while five specifically used non-CMIA
reference assays. Given the association between false
negatives and a low OD/CO, it was reasonable to pre-
sume sensitivity is reduced with low HBsAg levels.
CMIA has excellent analytical sensitivity (0.05 IU/ml)
[14–16], and can be used to quantitate HBsAg levels in
clinical specimens [17]. These platforms are the most
widely used in clinical practice [18] given automation
and high throughput, with data on kinetics and sensitiv-
ity in HIV-HBV co-infection.
Data extraction and quality assessment
Two authors (AA and OV) independently extracted data
and reached agreement on the following variables: study
author and year; study location and design; specimens
tested; eligibility criteria; index test and reference stand-
ard, including manufacturer; raw cell numbers (true pos-
itives, false negatives, false positives, true negatives); HIV
co-infection; sources of funding and reported conflict of
interest.
Study quality was evaluated using the QUADAS-2 tool
[19], which evaluates risk of bias (patient selection, index
test, reference standard, and patient flow through) and
applicability concerns (patient selection, index test, ref-
erence standard).
Data analysis and synthesis
We conducted meta-analysis pooling data using the
DerSimonian-Laird bivariate random effects model
(REM) to calculate pooled sensitivity and specificity with
95% confidence intervals (CI), which were used to esti-
mate positive and negative likelihood ratios (PLR, NLR).
Heterogeneity was assessed by visual inspection of forest
plots and estimates of τ2 for diagnostic odds ratios (DOR)
to measure between study variability. We performed sub-
group analysis based on study year (2005–2015); tests
brands (for brands that were evaluated in at least three
studies); sample type and HIV status. All statistical analysis
and figures were generated using Meta-Disc© version
1.4.7. (XI Cochrane Colloquium Barcelona, Spain).
Results
Study selection and characteristics
A total of 11,589 citations were identified, and 293 full-
text articles examined which identified 40 studies meeting
pre-defined criteria (Fig. 1). Of the included studies, 33
compared RDTs [14, 18, 20–47] and/or EIAs [14, 47–50]
against an immunoassay reference standard, of which
five focused on accuracy in HIV-positive individuals
[26, 44–47]. Seven studies compared RDTs [51–53]
and/or EIAs [53–57] against a NAT reference stand-
ard, of which 3 had data from HIV-positive patients
[53, 56, 57]. Studies were all either cross-sectional or
case-control, predominantly in the laboratory setting,
and performed in a broad range of populations, including
healthy volunteers, blood donors, pregnant women, in-
carcerated adults, HIV and hepatitis patient cohorts with
confirmed HBV infection. The prevalence of HBV ranged
from 1.9 to 84% in populations tested. A mixture of
serum, plasma and whole blood was used for RDTs, while
studies of EIAs were performed on serum or plasma sam-
ples. Study characteristics are presented in Tables 1, 2
and 3.
Assessment of the quality of the studies
The QUADAS-2 assessment for risk of bias of each study,
including sub-studies deriving separate data points is pre-
sented in (Fig. 2a, b), with a summary in (Fig. 3). Bias in
patient selection was generally attributable to a case-
control study design (38%), or from enrolment of highly
selected populations such as blood donors or those with
known hepatitis B virus infection. Risk of bias from the
index test was most commonly due to insufficient report-
ing of blinding or evaluation of RDTs which are no longer
commercially available. Although the majority of studies
did not specify the exact time interval between perform-
ance of the index and reference assays, it was assumed to
be at low risk of bias as the assays were performed on the
same sample. Applicability was judged to be higher risk
for bias predominantly due to inclusion of older studies,
those that evaluated tests which are no longer commer-
cially available or studies using a NAT reference.
Diagnostic accuracy of rapid tests for HBsAg detection
Thirty studies [14, 18, 20–47] assessed the accuracy of
33 different brands of RDTs in 23,716 individuals, which
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resulted in 63 data points for sensitivity and specificity.
The reference standards used were CMIA in 5 studies,
MEIA in 3 studies, and EIA/ELISA in 25 studies, with 3
studies using more than one type of reference assay.
Test evaluations were conducted in 23 countries: six
studies were conducted in high-income country studies
[23, 27, 29, 32, 38, 42], two in upper-middle income
country studies [14, 34], nine in lower-middle income
[21, 24, 28, 30, 31, 33, 35, 39, 47], and six in low income
[18, 20, 22, 40, 43, 46] countries, with income levels clas-
sified according to the World Bank ranking criteria. The
overall pooled sensitivity and specificity were 90.0%
(95% CI: 89.1, 90.8) and 99.5% (95% CI: 99.4, 99.5), re-
spectively. The positive and negative likelihood ratios
were 117.5 (95% CI: 67.7, 204.1) and 0.10 (95% CI 0.07,
0.14), respectively. Visual and statistical heterogeneity
(τ2 = 6.84) was present for pooled analyses of sensitivity
and specificity; however, the range in sensitivity values
(0.50 to 1.00) was much broader than the range in speci-
ficity values (0.86 to 1.00 in all studies except for 1)
[Fig. 4; Tables 2, 4 and 5].
Most studies used serum or plasma samples. Eight
studies had data evaluating five RDTs using capillary or
venous whole blood [18, 21, 23, 32, 33, 39, 44, 45],
Fig. 1 PRISMA flow Diagram of included studies
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including two that were in exclusively HIV-positive indi-
viduals [44, 45]. Pooled sensitivity and specificity in ca-
pillary or venous whole blood were comparable to
plasma or serum at 91.7% (95% CI: 89.1, 93.9) and 99.9%
(95% CI: 99.8, 99.9). Visual and statistical heterogeneity
(τ2 = 1.69) were somewhat less among these studies as
compared with those described above using a mixture of
clinical samples [Fig. 5; Tables 2, 4 and 5].
Five studies [26, 44–47] evaluated three RDTs in 2596
HIV-positive patients, with a pooled sensitivity and spe-
cificity of 72.3% (95% CI: 67.9, 76.4) and 99.8% (95% CI:
99.5, 99.9), respectively. Visual and statistical heterogen-
eity was reduced (τ2 = 1.12). Only one sub-study [18]
had extractable data for 224 HIV-negative chronic HBV
patients who were HBV treatment naïve [Fig. 6; Tables 2,
4 and 5].
Studies published since 2005 reported lower sensi-
tivity compared to the nine articles published before
2005 [20, 27, 30, 32, 33, 36, 38, 40, 42]. Pooled sensitivity
was 96.9% (95% CI: 96.0, 97.7) and 86.4% (95% CI: 85.2,
87.5) for studies before and after 2005 respectively [Fig. 7a
and b; Table 4]. Five studies [14, 18, 25, 46, 47] published
since 2010 evaluating tests against a newer CMIA refer-
ence specifically also reported lower pooled sensitivity of
80.4% (95% CI: 77.9, 82.6), with reduced heterogeneity
(τ2 = 1.26). Pooled specificity was above 99% irrespective
of publication date [Fig. 7b; Table 5].
Stratifying by test brand did not substantially reduce
heterogeneity. Data for all 50 brands of RDTs and EIAs
evaluated [Table 5; Additional file 2] demonstrates broad
ranges in sensitivity results within individual brands,
with generally high (>90%) specificity, as previously
noted. Only four test brands were evaluated in three or
more studies. Determine HBsAg was evaluated in ten
studies, only one published before 2008 [18, 23, 26, 33,
34, 37, 41, 44, 45, 47]; pooled sensitivity and specificity
in 7730 samples were 90.8% (95% CI: 88.9, 92.4) and
99.1% (95% CI: 98.9, 99.4), respectively. Excluding one
outlier field study that reported a sensitivity of 56% and
specificity of 69% [37], the sensitivities ranged from 69%
to 100% and specificities from 93% to 100%. VIKIA
HBsAg was evaluated in three studies in 5242 patient
samples [18, 23, 47], all published after 2010, with
pooled sensitivity and specificity of 82.5% (95% CI: 77.5,
86.7) and 99.9% (95% CI: 99.8, 100), respectively.
BinaxNOW HBsAg was evaluated in three studies in
3542 patient samples [21, 27, 32], all published before
2007, with pooled sensitivity and specificity of 97.6%
(95% CI: 96.2, 98.6) and 100% (95% CI: 99.7, 100), re-
spectively. Serodia HBsAg was evaluated in three studies
on 1040 patient samples [33, 38, 42], all published before
2000, with pooled sensitivity and specificity of 95.8%
(95% CI: 93.4, 97.5) and 99.8% (95% CI: 99.1, 100),
respectively.
Diagnostic accuracy of laboratory immunoassays for
HBsAg detection
Five studies [14, 47–50], performed in China, Ghana,
Cambodia and Vietnam evaluated 8 EIAs against a
CMIA reference standard, in 1825 serum or plasma
samples, reported a pooled sensitivity and specificity of
88.9% (95% CI: 87.0, 90.6) and 98.4% (95% CI: 97.8,
98.8), respectively. The respective positive and negative
LRs were 46.8 (95% CI: 12.9, 170.0) and 0.04 (95% CI:
0.01, 0.13), with visible and statistical heterogeneity be-
tween studies (τ2 = 12.00). Outliers were from two
Chinese studies [14, 49] that evaluated two older ELISA
assays (KHB; Wantai) with a sensitivity lower than 90%
[Fig. 8; Tables 1 and 4].
One study [47] evaluated 3 different EIAs in 838 HIV-
positive patients. Results were homogenous between
tests, with pooled sensitivity and specificity of 97.9%
(95% CI: 96.0, 99.0) and 99.4% (95% CI: 99.0, 99.7),
respectively, for a positive and negative LR of 167.3
Table 1 Study characteristics of laboratory-based immunoassays against laboratory reference standard [EIA vs EIA]s
Study
[author, year]
Location
[country, city]
Sample
size
Study
design
Setting Sample
type
Assay under evaluation
[type, brand]
Reference standard
[type, brand]
Liu, 2014 [14] China 250 CC Hospital patients; outpatients
(Preselected based on CMIA
quantitative results)
Serum ECLIA, Cobas
ELISA, Wantai
CMIA, Architect HBsAg
Peng, 2011 [49] China 498 CC Hospital patients
(Preselected based on S/CO
from KHB screen)
Serum ELISA, KHB CMIA, Architect HBsAg
Geretti, 2010 [47] Ghana, Kumasi 838 CS – CSQ HIV clinic (1/3 on lamivudine) Serum CMIA, Architect HBsAg
CMIA, Liaison Ultra
EIA, Murex v3
CMIA, Architect/ Liaison
EIA, Murex v3a
Ol, 2009 [48] Cambodia 120 CS – CSQ Blood donors (rural community) Serum ELISA, Monolisa CMIA, Architect HBsAg
Viet, 2012 [50] Vietnam 119 CS – CSQ Blood donors (rural community) Serum EIA, Monolisa Ultra CMIA, Architect HBsAg
aReactive all three assays OR reactive in one assay with neutralisation
CC case control, CMIA chemiluminescent microparticle enzyme immunoassay, CS cross-sectional, CSQ consecutive patients, ECLIA electrochemiluminescent
immunoassay, EIA enzyme immunoassay, ELISA enzyme linked immunosorbent assay, KHB KHB Ltd., Shanghai, S/CO signal cut-off ratio
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(95% CI: 95.1, 294.1) and 0.02 (95%CI: 0.01, 0.04) re-
spectively [Table 4].
Diagnostic accuracy compared to a nucleic acid reference
standard
Rapid diagnostic tests
Three studies [51–53] evaluated 7 RDTs in samples
from 510 patients against a NAT reference standard,
although some samples were used for multiple testing
episodes with different tests. One study [52] used
plasma from Nigerian repeat blood donors. Sensitiv-
ities ranged from 38% to 99% and specificities ranged
from 94 to 99%. Overall pooled sensitivity and specifi-
city were 93.3% (95% CI: 91.3, 94.9) and 98.1% (95%
CI: 97.0, 98.9), respectively, with significant hetero-
geneity in terms of sensitivity [Fig. 9; Table 3; Add-
itional file 3]. One case-control study [51] evaluating
five different tests in 240 Iranian patients, had signifi-
cantly higher sensitivity and specificity compared to
the other studies, contributing to the overall statistical
heterogeneity (τ2 = 5.82).
One study [52] assessed RDT performance in 113
HIV-negative Nigerian repeat blood donors, with clinical
sensitivity 60% (95% CI: 36, 81); of note the 8 false nega-
tive samples were anti-HBc-positive and regarded as oc-
cult hepatitis B, with median HBV viral load 51 IU/ml
(range 30–80 IU/mL). The final study [53] had data for
consecutive HIV-positive and negative individuals in
Uganda; sensitivity was lower in the 83 HIV-positive pa-
tients compared to the 74 HIV-negative individuals at
38% (95% CI: 23, 54) and 55% (95% CI: 32, 76) respect-
ively [Table 3; Additional file 3].
Enzyme immunoassays
Five studies [53–57] evaluated EIAs based on a NAT ref-
erence, using samples from 1194 patients. Pooled sensi-
tivity and specificity were 75.7% (95% CI: 72.1, 79.1) and
86.1% (95% CI: 83.8, 88.2), respectively. The respective
positive and negative LRs were 7.2 (95% CI: 4.4, 11.8)
and 0.30 (95%CI: 0.19, 0.46), with reduced heterogeneity
compared to studies evaluating RDTs (τ2 = 0.90) [Fig. 10;
Table 3; Additional file 3].
Three studies [53, 56, 57] had data from 442 HIV-
positive patients in Uganda and South Africa, with
pooled sensitivity and specificity of 57.9% (95% CI: 49.8,
65.6) and 95.8% (95% CI: 92.7, 97.8), respectively. The
corresponding pooled sensitivity and specificity for the
202 HIV-negative patients across two of these studies
[53, 57] were 83.3% (95%CI: 69.8, 92.5) and 85.7% (95%
CI: 79.2, 90.8), respectively [Table 3; Additional file 3].
Discussion
Study findings
Our systematic review and meta-analysis shows that
both RDTs and EIAs had excellent specificity for the de-
tection of HBsAg when compared to laboratory-based
assays. Although the pooled sensitivity of RDTs was only
90% compared to laboratory based EIAs, the 10% lower
sensitivity of RDTs may be an acceptable trade-off for
opportunities to use RDTs to increase access to testing
Table 3 Study Characteristics of rapid-diagnostic tests (RDTs) or laboratory-based immunoassays (EIA) against nucleic-acid test
reference standards [RDT/EIA vs NAT]
Study [author, year] Location
[country, city]
Sample
size, n
Study
design
Setting Sample Test under evaluation
[type, brand]
Reference test
[type, brand]
Ansari, 2007 [51] Iran, Urumieh 240 CC Hospital patients S RDT, ACON
RDT, Atlas
RDT, Blue Cross
RDT, Cortez
RDT, DIMA
RDT, Intec
qPCR
Nna, 2014 [52] Nigeria 113 CS Blood donors (repeat) – all
were HIV negative
P RDT, ACON Nested PCR;
qPCR for positive
Seremba, 2010 [53] Uganda 157 CS - CSQ Hospital patients (emergency
medical ward), including
HIV+ (83) and HIV- (74).
S RDT, Cortez
EIA, ADVIA
PCR
Khadem-Ansari, 2014 [54] Iran, Urumieh 350 CS – CSQ? Hospital patients - referred
as? HBV
S ChLIA, Liaison Rt-PCR
Lukhwareni, 2009 [56] South Africa 192 CC HIV cohort - pre ART S ChLIA, Elecsys qPCR
Mphahlele, 2006 [57] South Africa 295 CC Hospital patients, HIV+ (167)
and HIV- (128)
S EIA, AxSYM Nested PCR
Olinger, 2007 [55] Nigeria, Ibadan 200 CS Hospital patients - Liver
disease, HIV
S MEIA, AxSYM v2
ChLIA, Elecsys
ELFA, VIDAS Ultra
rtPCR and nested PCR
CC case control, ChLIA chemiluminescent immunoassay, CMIA chemiluminescent microparticle enzyme immunoassay, CS cross-sectional, CSQ consecutive
patients, ECLIA electrochemiluminescent immunoassay, EIA enzyme immunoassay, ELFA enzyme linked fluorescent assay, ELISA enzyme linked
immunosorbent assay, MEIA microparticle enzyme immunoassay, qPCR quantitative PCR, RDT rapid diagnostic test, rtPCR realtime PCR
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Fig. 2 Risk of bias and applicability for studies using (a) laboratory, or (b) nucleic-acid reference standard
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):698 Page 28 of 196
to all levels of the health care system. Significant hetero-
geneity with a broad range of sensitivity estimates was
observed across studies and different brands as well as
across studies for the same brand. Accuracy and quality
of RDTs should be important considerations in test se-
lection for national programmes.
Apart from the rapid results and ease of use, RDTs
can be used with whole blood from a finger prick com-
pared to the necessity of processing blood samples to
obtain serum or plasma for use with EIAs. Our review
showed that accuracy using capillary or venous whole
blood was not significantly different from studies using
plasma or serum, which offers convenient specimen
sampling outside of laboratory settings without com-
promising test accuracy.
None of the RDTs met minimum requirements for
analytical sensitivity (i.e. limit of detection [LOD] of
0.130 IU/mL) required by regulatory authorities such as
the European Union; WHO prequalification assessment
studies indicate a 50–100 fold lower LoD for EIAs
(0.1 IU/mL) compared to RDTs (2–10 IU/mL) [15].
Clinical sensitivity is however unlikely to be greatly re-
duced as the majority of chronic HBV is associated with
blood HBsAg concentrations well above 10 IU/mL and
false-negative HBsAg RDTs are associated with lower
HBsAg and viral load, presence of HBsAg mutants, or
specific genotypes [15, 23, 34, 47].
We found lower sensitivity of RDTs in HIV-positive
individuals; however, there did not appear to be a similar
reduction in the single study assessing three different
EIAs in this cohort using an EIA reference with neutral-
isation [47]. The reasons for the apparent lower per-
formance are unclear. Studies quantifying HBsAg found
that in the context of co-infection, most false negatives
had lower concentrations of HBsAg and generally lower
HBV DNA than true positives [46, 47]. HIV-reverse
transcriptase inhibitors active against HBV can modestly
reduce HBsAg levels and therefore detection by RDTs
[58–60]; patients treated for a median 47 months dem-
onstrated significantly lower median HBsAg levels com-
pared to untreated patients (3.32log10 vs 4.23log10)
(p = 0.001), with the most marked reduction in HBeAg
positive patients and those with a more robust improve-
ment of CD4 from nadir on cART [61]. In our review,
the two studies with preserved sensitivity were in exclu-
sively ART-naïve patients with median CD4 175 cell/uL
[26] and 250 cells/uL [44]. Studies with sensitivity less
than 80% were in cohorts which included patients on
lamivudine-containing ART [46, 47] or ART-naïve with
a higher median CD4 (350 cells/uL) [45]. As most pa-
tients in the field will be ART-naïve as part of dual
screening programmes, the clinical impact of reduced
sensitivity could be less significant as most will have
detectable higher HBsAg levels. Another theoretical
Fig. 3 Risk of bias and applicability summary for using (a) laboratory, or (b) nucleic-acid reference standard
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explanation in the context of ART is that given overlap-
ping surface and polymerase genes, lamivudine with its
low genetic barrier to resistance could promote the
emergence of surface genome variants undetectable by
standard assays; mutations in the “a” antigenic determin-
ant region of HBsAg can cause conformational changes
leading to decreased accuracy of diagnosis [62]. This
was, however, only a minor contributor to reduced per-
formance in the single study assessing mutants in HIV-
HBV co-infection [47], with reduced analytical sensitivity
of assays more important. Further reasons for reduced
sensitivity of lateral flow devices in the context of HIV
could be due to either an increased presence of blocking
antibodies to HBsAg and immune-complex formation in
Fig. 4 Forest plot with accuracy of RDT compared to EIA
Table 4 Summary pooled diagnostic accuracy of HBsAg assays using EIA reference standards
Index test HIV status Studies,
n
Sample size
(range), n
Data points,
n
Pooled clinical accuracy (95% CI) Likelihood ratios (95% CI)
Sensitivity Specificity Positive Negative
RDT NA 30 23,716 (25–3928) 63 90.0 (89.1–90.8) 99.5 (99.4–99.5) 117.5 (67.7–204.1) 0.10 (0.07–0.14)
HIV-positive 5 2596 (75–973) 6 72.3 (67.9–76.4) 99.8 (99.5–99.9) 192.6 (77.4–497.2) 0.29 (0.22–0.38)
EIA NA 5 1825 (119–838) 8 88.9 (87.0–90.6) 98.4 (97.8–98.8) 46.8 (12.9–170.0) 0.04 (0.01–0.13)
HIV-positive 1 838 3 97.9 (96.0–99.0) 99.4 (99.0–99.7) 167.3 (95.1–294.1) 0.02 (0.01–0.04)
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HIV-associated hypergammaglobulinaemia, or the pro-
zone effect at high antigen concentrations. Assay sensi-
tivity also varies depending on genotypes, and it could
be that regions with high HIV co-infection also have a
higher proportion of poorly detected genotypes. Finally,
as studies were cross-sectional in nature, we can’t assess
and compare the true prevalence of chronic HBV in co-
horts or the progression of disease – it may be that there
is an increased prevalence of acute and/ or chronic HBV
in HIV-cohorts, with RDTs missing low level HBsAg in
patients who are in the process of seroconverting from
their illness. Further studies are required following up
patients with HIV and full HBV serology to further as-
certain reasons for and the clinical impact of reduced
sensitivity of RDTs.
Accuracy of both HBsAg RDTs and EIAs compared to
a NAT reference was generally lower, especially amongst
HIV-positive cohorts; sensitivity of RDTs was generally
<60%, with one laboratory based case-control study
evaluating six RDTs contributing to potential over-
estimation of pooled sensitivity [51]. Although NAT as-
says are not optimal reference standards for HBsAg,
given the complex relationship between viral kinetics of
HBV DNA and levels of HBsAg, NAT assays are
nevertheless useful markers of viremia and disease activ-
ity to guide treatment, as well as the detection of occult
hepatitis B. Occult hepatitis B (OHB) is defined as the
presence of HBV DNA in serum or liver tissue with un-
detectable HBsAg [57]. Studies in ART-naïve East [63]
and West-African [64] patients found an OHB preva-
lence of 10–15%, with significantly lower HBV viral
loads in these individuals compared to those with
detectable HBsAg [47]. Knowledge of HBeAg status and
ART regimes is relevant, as dually active ART could suc-
cessfully suppress HBV viral load and HBsAg detection
[58, 59]. Now that it is possible to use CMIA to quanti-
tate HBsAg, and levels of HBsAg has been correlated
with intrahepatic cccDNA clearance during treatment,
further research should explore the use of CMIA to
quantitate HBsAg levels as potential markers of disease
resolution.
The pooled sensitivity for RDTS in this review is lower
than that reported in previous systematic reviews
(pooled sensitivities were 97.1% [11], 94.8% [10], and
98.1% [9]). This may be due to the use of different inclu-
sion criteria in the prior reviews. Accuracy estimates
tend to be higher when the RDTs were evaluated in la-
boratory settings using archived evaluation panels than
Table 5 Summary pooled diagnostic accuracy of rapid HBsAg assays stratified by study, patient, index and reference tests
Subgroup Studies, n Sample size, n Points, n Pooled clinical accuracy (95% CI) Likelihood ratios (95% CI)
Sensitivity Specificity Positive Negative
Study Pre 2005 9 8854 (206–2754) 19 96.9 (96.0–97.7) 99.7 (99.6–99.8) 265.5 (106.1–664.5) 0.06 (0.03–0.10)
Post 2005 21 14,862 (25–3956) 44 86.4 (85.2–87.5) 99.4 (99.2–99.5) 84.6 (43.6–164.6) 0.13 (0.09–0.18)
HIV-positive 5 2596 (75–973) 6 72.3 (67.9–76.4) 99.8 (99.5–99.9) 192.6 (77.4–497.2) 0.29 (0.22–0.38)
Specimen type Whole blood 8 6889 (25–3956) 11 91.7 (89.1–93.9) 99.9 (99.8–99.9) 346.6 (157.6–762.4) 0.09 (0.06–0.14)
Index test Determine 10 7730 (75–2472) 12 90.8 (88.9–92.4) 99.1 (98.9–99.4) 239 (17.1–33,300) 0.077 (0.035–0.168)
VIKIA 3 5242 (476–3928) 3 82.5 (77.5–86.7) 99.9 (99.8–100) 1070 (376–3060) 0.108 (0.026–0.458)
BinaxNOW 3 3542 (137–2463) 6 97.6 (96.2–98.6) 100 (99.7–100) 221 (36.1–1350) 0.045 (0.016–0.128)
Serodia 3 1040 (250–462) 3 95.8 (93.4–97.5) 99.8 (99.1–100) 285 (71.4–1140) 0.045 (0.029–0.069)
Reference test CMIA 5 3521 (227–1768) 9 80.4 (77.9–82.6) 99.0 (99.6–99.3) 58.5 (31.3–109) 0.141 (0.074–0.268)
Fig. 5 Forest plot with accuracy of RDT compared to EIA, using whole blood only
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Fig. 6 Forest plot with accuracy of RDT compared to EIA, in HIV-positive patients
a
b
Fig. 7 Forest plot with accuracy of RDT compared to EIA, for studies (a) before and (b) after 2005
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when they are evaluated in field settings in patients at-
tending a clinical facility, who may have a variety of
underlying conditions or co-infections that affect test
performance. In the case of RDTs, the tests may be
stored and used in uncontrolled physical environments
and performed by users who may not have ever per-
formed a test. Data on the clinical performance of these
assays are more relevant for developing guideline
recommendations.
Sources of heterogeneity
Statistical heterogeneity is observed in most diagnostic
accuracy reviews. None of the sub-analyses performed
eliminated heterogeneity, which could be due to a num-
ber of factors. Variability of assays could result in statis-
tical heterogeneity. This persisted despite subgrouping
by brand, although it should be noted that the same
brand often undergoes minor product changes and mod-
ifications over time, particularly with changes in the
manufacturer.
Variation in reference standards also contributed to
different RDT sensitivity. Pooled sensitivity of RDTs was
lower when compared to a CMIA reference standard
(80.4%) than a reference including non-CMIA technol-
ogy (90.0%). ELISA/EIA based assays in particular per-
formed poorly relative to other immunoassays when
compared to a CMIA reference [14, 49]; different signal
cut-off ratio’s (S/CO) and use of the ‘gray zone’ im-
proved sensitivity at the expense of specificity. Accuracy
of tests also varies depending on the phase of chronic
HBV infection, with reduced sensitivity more common
in the inactive carrier state compared to the active repli-
cative phase. In a Gambian field study [18], the majority
(94.7%) of false-negative RDT results were from inactive
carriers; they were all HBeAg negative with normal ALT
levels, more commonly female (p = 0.05) and had lower
median quantitative HBsAg levels compared to true pos-
itives (1.2 IU/mL vs 875 IU/mL) (p = 0.0002). Of note,
RDTs also had a lower limit of detection in the field
(26.5 IU/mL) compared to the laboratory setting
(2.8 IU/mL), although the clinical sensitivity was similar,
albeit in a study where field staff were all adequately
trained. Although inactive carriers often do not warrant
treatment, 17% had elevated liver stiffness and were pre-
cirrhotic, so would have benefited from antiviral therapy
[65]. Further studies are required to assess the clinical
impact of reduced RDT sensitivity, particularly those
performed in the field.
Finally, the large variability in study design across the
literature is a significant source of heterogeneity. A large
number of case-control studies with pre-selection of
known cases and controls tend to over-estimate accur-
acy, in part due to the higher quantitative ranges of
HBsAg in those with known active disease. Performance
in higher income countries tends to be less heteroge-
neous [11], while reduced accuracy observed in low-
resource settings may be due to insufficient training or
lack of quality assurance systems [66]. Pooled sensitivity
Fig. 8 Forest plot with accuracy of EIA compared to EIA
Fig. 9 Forest plot with accuracy of RDT compared with NAT
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and specificity tend to be lower when the RDTs are used
in the field compared to studies where they were per-
formed in laboratory settings [26, 37].
Study strengths
Strengths of this review include evaluation of a compre-
hensive evidence base, use of a pre-specified protocol in-
corporating numerous major scientific databases, and
assessment of additional areas relevant to HBsAg diag-
nostic testing, notably comparison with NAT and poten-
tial impact of occult hepatitis B. We identified 11
additional articles [18, 22, 25, 28, 29, 35, 37, 43, 45–47]
not found in the most recent systematic review assessing
the diagnostic accuracy of RDTs [11]. The pooled sensi-
tivity for RDTs in this review is lower than reported in
previous systematic reviews (pooled sensitivities of
97.1% [11], 94.8% [10], and 98.1% [9]). Potential reasons
include the different inclusion criteria; previous reviews
included a mixture of studies of analytical performance
using serum panels and clinical studies. As previously
explained, accuracy estimates tend to be higher when
tests are evaluated in laboratory settings using archived
evaluation panels, with estimates less relevant for
informing the development of testing or operational
guidelines.
We included evaluations of both RDTs and EIAs, in
addition to evaluation using a NAT reference, and as
such are able to evaluate the effects of different types of
HBsAg assays and different types of reference assays.
Limitations
Our study has a number of limitations. Many studies
were case-control designs or evaluated cohorts known
to over-estimate accuracy. We were unable to assess
diagnostic accuracy specifically in field studies as defini-
tions of “in the field” are open to interpretation with
methods poorly described in many papers. Only two
studies (1, 2) specifically mention the use of RDTs in the
field. Since the purpose of our review was to assess clin-
ical performance, we included papers describing evalua-
tions of test performance in patients in clinical settings
and not laboratory based evaluations using reference
panels. Some analyses were based on a small number of
patients and few positive samples. We were unable to
explore potential sources of heterogeneity due to geno-
type, stage and severity of infection or other co-
infections; genetic information has long been suspected
to impact on diagnostic accuracy [67–72], and mutants
are rapidly evolving such that prevalence of specific
types cannot be determined on historical data. The use
of different reference standards makes pooling across
studies difficult; this is further complicated by rapid
changes in technology and analytical sensitivity com-
bined with suboptimal reporting of LOD in both index
tests and reference standards. For studies using NAT as
a reference, assays were not standardized, with poor
reporting of testing, albeit all were according to the
manufacturer’s instructions; some used pooled NAT of
HBsAg negative sample [55, 57], while others described
inadequate detail for qPCR methodology [51, 54]. Fi-
nally, the natural history of diagnostic markers in
chronic hepatitis B is more complex than most viral in-
fections, with transient low level asynchronous quantita-
tive fluctuations of HBsAg and DNA recognised in
uncomplicated chronic HBV [73]. Such cases are clinic-
ally less severe and of lower priority than persons with
higher levels of viremia, but are likely to impact esti-
mates of sensitivity and specificity.
Implications
The global burden and relative rank of hepatitis B in
terms of health loss has increased in the last two de-
cades, unlike most communicable diseases. Implementa-
tion of timely and accurate testing strategies in many
endemic settings is poor, hindering the linkage to care.
Rapid tests are suited to improve the uptake of testing in
resource limited settings, particularly amongst remote
and vulnerable populations, but evidence is lacking for
the impact of testing at the point of care on service de-
livery and linkage to and uptake of subsequent care. Re-
search is needed on the clinical impact of reduced RDT
sensitivity given the association of low quantitative
HBsAg missed by testing with inactive carriers and min-
imal disease progression [74]. Validation of assays in the
Fig. 10 Forest plot with accuracy of EIA compared with NAT
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):698 Page 34 of 196
context of immune escape variants and using less inva-
sive collection methods would support the development
of demographic specific testing strategies. Finally, con-
cerns about the low sensitivity of RDTs in HIV positive
cohorts warrant particular evaluation, given the growing
global challenge posed by co-infection, drug resistance
and inadequate approaches to management of HBV and
prevention of mother to child transmission in pregnant
women [75]. Studies assessing the impact of viral load,
CD4 and ART regimen exposure on HBsAg diagnostic
accuracy are urgently needed, particularly the potential
prudence of repeat HBsAg testing after a certain time in
high risk individuals who may have seroconverted or
progressed.
Conclusion
In summary, this meta-analysis demonstrates that RDTs
to detect HBsAg, performed on either serum, plasma or
whole blood, have a pooled sensitivity of >90% and spe-
cificity of >98% compared to laboratory methods of
HBsAg detection, using EIAs as the reference standard.
Sensitivity varies widely overall and within brands of
HBsAg tests. Sensitivity of RDTs may be lower in HIV-
positive individuals, although possibly less so in ART-
naïve individuals who would benefit most from screen-
ing using dual HIV-HBV RDTs in settings with limited
access to laboratories. Further research is needed to as-
sess the impact of using RDTs in a variety of settings
and populations. WHO guidelines currently recommend
a role for RDTs in scaling up HBsAg testing in settings
with poor access to or lack of existing laboratory infra-
structure, such as remote settings or with hard-to-reach
populations. Their use may also be appropriate in high-
income countries to increase the uptake of hepatitis test-
ing in populations that may be reluctant to test or have
poor access to health-care services and in outreach pro-
grammes [12].
Additional files
Additional file 1: Search strategy. (DOC 80 kb)
Additional file 2: Table S1. Summary pooled diagnostic accuracy of
HBsAg assays by brand. (DOC 126 kb)
Additional file 3: Table S2. Summary pooled diagnostic accuracy of
HBsAg assays using NAT reference standards. (DOC 75 kb)
Abbreviations
ART: Anti-retroviral therapy; CC: Case-control studies; CI: Confidence
interval; CMIAs: Chemiluminescent microparticle immunoassays; CS: Cross-
sectional studies; DBS: Dried blood spot; DOR: Diagnostic odds ratio;
ECLIA: Electrochemiluminescent immunoassay; EIA: Enzyme immunoassay;
ELISA: Enzyme-linked immunosorbent assay; HBcAb: Hepatitis B core antibody;
HBeAg: Hepatitis B ‘e’ antigen; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis
B Virus; HCV: Hepatitis C Virus; HIV: Human Immunodefiency virus; LOD: Limit of
detection; LR: Likelihood ratio; MEIA: Microparticle enzume immunoassay;
NAT: Nucleic acid testing; NLR: Negative likelihood ratio; PLR: Positive likelihood
ratio; POC: Point-of-care; PRISMA: Preferred reporting items for systematic
reviews and meta-analyses; QUADAS: Quality assessment of diagnostic
accuracy studies; RDTs: Rapid diagnostic tests; REM: Random effects
model; RIA: Radioimmunoassay; S/CO: Signal cut-off ratio’s; WHO: World
Health Organization
Acknowledgements
The authors acknowledge the support of WHO, London School of Hygiene &
Tropical Medicine, SESH Global and UNC Project China.
Availability of data and materials
The dataset supporting the conclusions of this article is included within the
article’s additional file.
About this supplement
This article has been published as part of BMC Infectious Diseases Volume 17
Supplement 1, 2017: Testing for chronic hepatitis B and C – a global
perspective. The full contents of the supplement are available online at
https://bmcinfectdis.biomedcentral.com/articles/supplements/volume-17-
supplement-1.
Authors’ contributions
RP and JDT designed the study, with input from JF in building search
algorithm and retrieving articles. All authors contributed to study
optimisation. AA, HK and OV identified and extracted data. AA was
responsible for overall data synthesis and wrote the manuscript with input
from OV, JT and RP. All authors read and approved the final manuscript.
Funding
This work was supported by funding from the World Health Organization to
RP at LSHTM, National Institutes of Health National Institute of Allergy and
Infectious Diseases 1R01AI114310–01 to JT, and UNC-South China STD Re-
search Training Centre Fogarty International Centre 1D43TW009532–01 to JT.
Publication charges for this article have been funded by the World Health
Organization.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1London School of Hygiene and Tropical Medicine, Keppel St, London WC1E
7HT, UK. 2Guangdong Provincial Center for Skin Diseases and STI Control,
Guangzhou, China. 3School of Medicine, University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA. 4School of Public Health, Sun Yat-sen
University, Guangzhou, China. 5Oregon Health & Science University, Portland,
OR, USA. 6HIV/ AIDS Department, World Health Organisation, Geneva,
Switzerland.
Published: 1 November 2017
References
1. World Health Organization. Global hepatitis report 2017. 2017: Geneva.
http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
2. Ganem D, Prince AM, Hepatitis B. Virus infection–natural history and clinical
consequences. N Engl J Med. 2004;350(11):1118–29.
3. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global,
regional, and national age-sex specific all-cause and cause-specific mortality
for 240 causes of death, 1990-2013: a systematic analysis for the global
burden of disease study 2013. Lancet. 2015;385(9963):117–71.
4. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et
al. The global burden of viral hepatitis from 1990 to 2013: findings from the
global burden of disease study 2013. Lancet. 2016;388(10049):1081–8.
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):698 Page 35 of 196
5. World Health Organization. Guidelines for the prevention, care and
treatment of persons with chronic hepatitis B infection. 2015: Geneva.
http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/
6. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect
of age on immunological response to hepatitis B vaccine in end-stage renal
disease. Aliment Pharmacol Ther. 2004;20(10):1053–62.
7. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et
al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review
and economic analysis. Health Technol Assess. 2007;11(34):1–206.
8. Qin XK, Li P, Han M, Liu JP. Xiaochaihu tang for treatment of chronic
hepatitis B: a systematic review of randomized trials. Zhong Xi Yi Jie He Xue
Bao. 2010;8(4):312–20.
9. Hwang SH, HB O, Choi SE, Kim HH, Chang CL, Lee EY, et al. Meta-analysis
for the pooled sensitivity and specificity of hepatitis B surface antigen rapid
tests. Korean journal of. Lab Med. 2008;28(2):160–8.
10. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pai NP. Rapid point-of-care first-
line screening tests for hepatitis B infection: a meta-analysis of diagnostic
accuracy (1980-2010). Am J Gastroenterol. 2012;107(9):1306–13.
11. Khuroo NS, Khuroo MS. Accuracy of rapid point-of-care diagnostic tests for
hepatitis B surface antigen-a systematic review and meta-analysis. Journal of
Clinical & Experimental. Hepatology. 2014;4(3):226–40.
12. World Health Organization. Guidelines on Hepatitis B and C Testing. 2017: Geneva.
http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/
13. World Health Organization. Hepatitis B surface antigen assays:
operational characteristics (phase I) Report 2. Geneva: World Health
Organization; 2004.
14. Liu C, Chen T, Lin J, Chen H, Chen J, Lin S, et al. Evaluation of the
performance of four methods for detection of hepatitis B surface antigen
and their application for testing 116,455 specimens. J Virol Methods. 2014;
196:174–8.
15. Scheiblauer H, El-Nageh M, Diaz S, Nick S, Zeichhardt H, Grunert HP, et al.
Performance evaluation of 70 hepatitis B virus (HBV) surface antigen
(HBsAg) assays from around the world by a geographically diverse panel
with an array of HBV genotypes and HBsAg subtypes.[Erratum appears in
Vox sang. 2010 may;98(4):581]. Vox Sang. 2010;98(3 Pt 2):403–14.
16. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al.
Quantitation of hepatitis B surface antigen by an automated chemiluminescent
microparticle immunoassay. J Virol Methods. 2004;115(2):217–22.
17. Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HL, Chan HL. The
role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;
66(2):398–411.
18. Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M, et al.
Validation of rapid point-of-care (POC) tests for detection of hepatitis B
surface antigen in field and laboratory settings in the Gambia, Western
Africa. J Clin Microbiol. 2015;53(4):1156–63.
19. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy
studies. Ann Intern Med. 2011;155(8):529–36.
20. Abraham P, Sujatha R, Raghuraman S, Subramaniam T, Sridharan G.
Evaluation of two immunochromatographic assays in relation to ‘RAPID’
screening of HBsAg. Indian J Med Microbiol. 1998;16:23–5.
21. Akanmu AS, Esan OA, Adewuyi JO, Davies AO, Okany CC, Olatunji RO, et al.
Evaluation of a rapid test kit for detection of HBsAg/eAg in whole blood: a
possible method for pre-donation testing. Afr J Med Med Sci. 2006;35(1):5–8.
22. Bjoerkvoll B, Viet L, Ol HS, Lan NT, Sothy S, Hoel H, et al. Screening test
accuracy among potential blood donors of HBsAg, anti-HBc and anti-HCV
to detect hepatitis B and C virus infection in rural Cambodia and Vietnam.
Southeast Asian J Trop Med Public Health. 2010;41(5):1127–35.
23. Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, et al.
Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large
cohort, France. J Hepatol. 2013;58(3):473–8.
24. Chameera EWS, Noordeen F, Pandithasundara H, Abeykoon AMSB.
Diagnostic efficacy of rapid assays used for the detection of hepatitis B virus
surface antigen. Sri Lankan. J Infect Dis. 2013;3(2):21–7.
25. Chevaliez S, Challine D, Naija H, Luu TC, Laperche S, Nadala L, et al.
Performance of a new rapid test for the detection of hepatitis B
surface antigen in various patient populations. J Clin Virol. 2014;59(2):
89–93.
26. Davies J, van Oosterhout JJ, Nyirenda M, Bowden J, Moore E, Hart IJ, et al.
Reliability of rapid testing for hepatitis B in a region of high HIV endemicity.
Trans R Soc Trop Med Hyg. 2010;104(2):162–4.
27. Clement F, Dewint P, Leroux-Roels G. Evaluation of a new rapid test for the
combined detection of hepatitis B virus surface antigen and hepatitis B
virus e antigen. J Clin Microbiol. 2002;40(12):4603–6.
28. Erhabor O, Kwaifa I, Bayawa A, Isaac Z, Dorcas IaS, I. Comparison of ELISA
and rapid screening techniques for the detection of HBsAg among blood
donors in Usmanu Danfodiyo university teaching hospital Sokoto, North
Western Nigeria. J Blood Lymph. 2014;4(2):124.
29. Gish RG, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, et al. A simple
and inexpensive point-of-care test for hepatitis B surface antigen detection:
serological and molecular evaluation. J Viral Hepat. 2014;21(12):905–8.
30. Kaur H, Dhanao J, Oberoi A. Evaluation of rapid kits for detection of HIV,
HBsAg and HCV infections. Indian J Med Sci. 2000;54(10):432–4.
31. Khan J, Lone D, Hameed A. Evaluation of the performance of two rapid
immunochromatographic tests for detection of hepatitis B surface antigen and
anti HCV antibodies using ELISA tested samples. AKEMU. 2010;16(1 S1):84–7.
32. Lau DT, Ma H, Lemon SM, Doo E, Ghany MG, Miskovsky E, et al. A rapid
immunochromatographic assay for hepatitis B virus screening. J Viral Hepat.
2003;10(4):331–4.
33. Lien TX, Tien NTK, Chanpong GF, Cuc CT, Yen VT, Soderquist R, et al. Evaluation
of rapid diagnostic tests for the detection of human immunodeficiency virus
types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City,
Vietnam. Am J Trop Med Hyg. 2000;62(2):301–9.
34. Lin YH, Wang Y, Loua A, Day GJ, Qiu Y, Nadala EC Jr, et al. Evaluation of a
new hepatitis B virus surface antigen rapid test with improved sensitivity. J
Clin Microbiol. 2008;46(10):3319–24.
35. Mutocheluh M, Owusu M, Kwofie TB, Akadigo T, Appau E, Narkwa PW. Risk
factors associated with hepatitis B exposure and the reliability of five rapid
kits commonly used for screening blood donors in Ghana. BMC Res Notes.
2014;7:873.
36. Mvere D, Constantine NT, Katsawde E, Tobaiwa O, Dambire S, Corcoran P.
Rapid and simple hepatitis assays: encouraging results from a blood donor
population in Zimbabwe. Bull World Health Organ. 1996;74(1):19–24.
37. Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C, et al.
Prevalence of infection with hepatitis B and C virus and coinfection with
HIV in medical inpatients in Malawi. J Infect. 2008;57(1):72–7.
38. Oh J, Kim TY, Yoon HJ, Min HS, Lee HR, Choi TY. Evaluation of Genedia®
HBsAg rapid and Genedia® anti-HBs rapid for the screening of HBsAg and
anti-HBs. Korean J Clin Pathol. 1999;19:114–7.
39. Ola SO, Otegbayo JA, Yakubu A, Aje AO, Odaibo GN, Shokunbi W. Pitfalls in
diagnosis of hepatitis B virus infection among adults nigerians. Niger J Clin
Pract. 2009;12(4):350–4.
40. Raj AA, Subramaniam T, Raghuraman S, Abraham P. Evaluation of an
indigenously manufactured rapid immunochromatographic test for
detection of HBsAg. Indian J Pathol Microbiol. 2001;44(4):413–4.
41. Randrianirina F, Carod JF, Ratsima E, Chretien JB, Richard V, Talarmin A.
Evaluation of the performance of four rapid tests for detection of
hepatitis B surface antigen in Antananarivo, Madagascar. J Virol Methods.
2008;151(2):294–7.
42. Sato K, Ichiyama S, Iinuma Y, Nada T, Shimokata K, Nakashima N. Evaluation
of immunochromatographic assay systems for rapid detection of hepatitis B
surface antigen and antibody, Dainascreen HBsAg and Dainascreen Ausab. J
Clin Microbiol. 1996;34(6):1420–2.
43. Upreti SR, Gurung S, Patel M, Dixit SM, Krause LK, Shakya G, et al. Prevalence
of chronic hepatitis B virus infection before and after implementation of a
hepatitis B vaccination program among children in Nepal. Vaccine. 2014;
32(34):4304–9.
44. Franzeck FC, Ngwale R, Msongole B, Hamisi M, Abdul O, Henning L, et al.
Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-
infected patients in rural Tanzania. PLoS One. 2013;8(3):e58468.
45. Hoffmann CJ, Dayal D, Cheyip M, McIntyre JA, Gray GE, Conway S, et al.
Prevalence and associations with hepatitis B and hepatitis C infection among
HIV-infected adults in South Africa. Int J STD AIDS. 2012;23(10):e10–3.
46. Honge BL, Jespersen S, Te DS, da Silva ZJ, Laursen AL, Krarup H, et al.
Hepatitis B virus surface antigen and anti-hepatitis C virus rapid tests
underestimate hepatitis prevalence among HIV-infected patients. HIV Med.
2014;15(9):571–6.
47. Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, Fraune M, et al.
Detection of highly prevalent hepatitis B virus coinfection among HIV-
seropositive persons in Ghana. J Clin Microbiol. 2010;48(9):3223–30.
48. Ol HS, Bjoerkvoll B, Sothy S, Van Heng Y, Hoel H, Husebekk A, et al.
Prevalence of hepatitis B and hepatitis C virus infections in potential blood
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):698 Page 36 of 196
donors in rural Cambodia. Southeast Asian J Trop Med Public Health. 2009;
40(5):963–71.
49. Peng J, Cheng L, Yin B, Guan Q, Liu Y, Wu S, et al. Development of an
economic and efficient strategy to detect HBsAg: application of “gray-
zones” in ELISA and combined use of several detection assays. Clin Chim
Acta. 2011;412(23–24):2046–51.
50. Viet L, Lan NT, Ty PX, Bjorkvoll B, Hoel H, Gutteberg T, et al. Prevalence of
hepatitis B & hepatitis C virus infections in potential blood donors in rural
Vietnam. Indian J Med Res. 2012;136(1):74–81.
51. Ansari MHK, Omrani MD, Movahedi V. Comparative evaluation of
immunochromatographic rapid diagnostic tests (strip and device) and PCR
methods for detection of human hepatitis B surface antigens. Hepat Mon.
2007;7(2):87–91.
52. Nna E, Mbamalu C, Ekejindu I. Occult hepatitis B viral infection among blood
donors in south-eastern Nigeria. Pathogens Global Health. 2014;108(5):223–8.
53. Seremba E, Ocama P, Opio CK, Kagimu M, Yuan HJ, Attar N, et al. Validity of
the rapid strip assay test for detecting HBsAg in patients admitted to
hospital in Uganda. J Med Virol. 2010;82(8):1334–40.
54. Khadem-Ansari MH, Omrani MD, Rasmi Y, Ghavam A. Diagnostic validity of
the chemiluminescent method compared to polymerase chain reaction for
hepatitis B virus detection in the routine clinical diagnostic laboratory. Adv
Biomed Res. 2014;3:116.
55. Olinger CM, Weber B, Otegbayo JA, Ammerlaan W, van der Taelem-Brule N,
Muller CP. Hepatitis B virus genotype E surface antigen detection with
different immunoassays and diagnostic impact of mutations in the preS/S
gene. Med Microbiol Immunol. 2007;196(4):247–52.
56. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased
detection of HBV DNA in HBsAg-positive and HBsAg-negative south African
HIV/AIDS patients enrolling for highly active antiretroviral therapy at a
tertiary hospital. J Med Virol. 2009;81(3):406–12.
57. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High
risk of occult hepatitis B virus infection in HIV-positive patients from South
Africa. J Clin Virol. 2006;35(1):14–20.
58. Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, et al.
Hepatitis B virus surface antigen levels: a guide to sustained response to
peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology.
2009;49(4):1141–50.
59. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al.
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for
chronic hepatitis B. Gastroenterology. 2011;140(1):132–43.
60. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al.
Hepatitis B surface antigen serum levels help to distinguish active from inactive
hepatitis B virus genotype D carriers. Gastroenterology. 2010;139(2):483–90.
61. Jaroszewicz J, Reiberger T, Meyer-Olson D, Mauss S, Vogel M, Ingiliz P, et al.
Hepatitis B surface antigen concentrations in patients with HIV/HBV co-
infection. PLoS One. 2012;7(8):e43143.
62. Sadeghi A, Shirvani-Dastgerdi E, Tacke F, Yagmur E, Poortahmasebi V,
Poorebrahim M, et al. HBsAg mutations related to occult hepatitis B virus
infection in HIV-positive patients result in a reduced secretion and
conformational changes of HBsAg. J Med Virol. 2017;89(2):246–56.
63. Mudawi H, Hussein W, Mukhtar M, Yousif M, Nemeri O, Glebe D, et al. Overt
and occult hepatitis B virus infection in adult Sudanese HIV patients. Int J
Infect Dis. 2014;29:65–70.
64. N'Dri-Yoman T, Anglaret X, Messou E, Attia A, Polneau S, Toni T, et al. Occult
HBV infection in untreated HIV-infected adults in cote d’Ivoire. Antivir Ther.
2010;15(7):1029–34.
65. European Association For The Study Of The L. EASL clinical practice
guidelines: management of chronic hepatitis B virus infection. J Hepatol.
2012;57(1):167–85.
66. Pruett CR, Vermeulen M, Zacharias P, Ingram C, Tayou Tagny C, Bloch EM.
The use of rapid diagnostic tests for transfusion infectious screening in
Africa: a literature review. Transfus Med Rev. 2015;29(1):35–44.
67. Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M. Evaluation of
sensitivity for wild type and mutant forms of hepatitis B surface antigen by
four commercial HBsAg assays. Clin Lab. 2004;50(3–4):159–62.
68. Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Ferey MP, Ebel A, et al.
Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg)
assays in detection of HBsAg mutant forms. J Clin Microbiol. 2006;44(7):2321–6.
69. Mizuochi T, Okada Y, Umemori K, Mizusawa S, Yamaguchi K. Evaluation of
10 commercial diagnostic kits for in vitro expressed hepatitis B virus (HBV)
surface antigens encoded by HBV of genotypes A to H. J Virol Methods.
2006;136(1–2):254–6.
70. Kuhns MC, McNamara AL, Holzmayer V, Lou SC, Busch MP. Frequency of
diagnostically significant hepatitis B surface antigen mutants. J Med Virol.
2007;79(SUPPL. 1):S42–S6.
71. Zhang R, Wang L, Li J. Hepatitis B virus transfusion risk in China: proficiency
testing for the detection of hepatitis B surface antigen. Transfus Med. 2010;
20(5):322–8.
72. Servant-Delmas A, Mercier-Darty M, Ly TD, Wind F, Alloui C, Sureau C, et al.
Variable capacity of 13 hepatitis B virus surface antigen assays for the detection
of HBsAg mutants in blood samples. J Clin Virol. 2012;53(4):338–45.
73. Maylin S, Sire JM, Mbaye PS, Simon F, Sarr A, Evra ML, et al. Short-term
spontaneous fluctuations of HBV DNA levels in a Senegalese population
with chronic hepatitis B. BMC Infect Dis. 2015;15(1):154.
74. Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, SN L, et al. Serum levels
of hepatitis B surface antigen and DNA can predict inactive carriers with
low risk of disease progression. Hepatology. 2016;64(2):381–9.
75. Kourtis AP, Bulterys M, DJ H, Jamieson DJ. HIV-HBV coinfection - a global
challenge. N Engl J Med. 2012;366(19):1749–52.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):698 Page 37 of 196
